These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
69 related articles for article (PubMed ID: 8073816)
21. Activator protein 1 DNA binding activity is decreased in lesional psoriatic skin compared with nonlesional psoriatic skin. Johansen C; Kragballe K; Rasmussen M; Dam TN; Iversen L Br J Dermatol; 2004 Sep; 151(3):600-7. PubMed ID: 15377346 [TBL] [Abstract][Full Text] [Related]
22. Serum and tissue angiotensin converting enzyme in patients with psoriasis. Huskić J; Mulabegović N; Alendar F; Ostojić L; Ostojić Z; Simić D; Milicević R; Naletilić M Coll Antropol; 2008 Dec; 32(4):1215-9. PubMed ID: 19149231 [TBL] [Abstract][Full Text] [Related]
23. The presence of anti-Fc gamma receptor autoantibodies is related to the clinical presentation of primary Sjögren's syndrome. Lamour A; Le Corre R; Pennec YL; Youinou P J Rheumatol; 1995 Dec; 22(12):2241-5. PubMed ID: 8835556 [TBL] [Abstract][Full Text] [Related]
24. Elevated interleukin-18 protein expression in early active and progressive plaque-type psoriatic lesions. Companjen A; van der Wel L; van der Fits L; Laman J; Prens E Eur Cytokine Netw; 2004; 15(3):210-6. PubMed ID: 15542445 [TBL] [Abstract][Full Text] [Related]
25. Psoriatic lesional skin exhibits an aberrant expression pattern of interferon regulatory factor-2 (IRF-2). van der Fits L; van der Wel LI; Laman JD; Prens EP; Verschuren MC J Pathol; 2003 Jan; 199(1):107-14. PubMed ID: 12474233 [TBL] [Abstract][Full Text] [Related]
26. Ethanol enhances the IFN-gamma, TGF-alpha and IL-6 secretion in psoriatic co-cultures. Ockenfels HM; Keim-Maas C; Funk R; Nussbaum G; Goos M Br J Dermatol; 1996 Nov; 135(5):746-51. PubMed ID: 8977675 [TBL] [Abstract][Full Text] [Related]
27. The role of heparin-binding EGF-like growth factor and amphiregulin in the epidermal proliferation of psoriasis in cooperation with TNFalpha. Yoshida A; Kanno H; Watabe D; Akasaka T; Sawai T Arch Dermatol Res; 2008 Jan; 300(1):37-45. PubMed ID: 17960400 [TBL] [Abstract][Full Text] [Related]
28. Influence of systemic cyclosporin A on interleukin-2 and epidermal growth factor receptor expression in psoriatic skin lesions. Horroccks A; Ormerod AD; Duncan JI; Thomson AW Clin Exp Immunol; 1989 Nov; 78(2):166-71. PubMed ID: 12412743 [TBL] [Abstract][Full Text] [Related]
29. Vascular endothelial growth factor in psoriasis: an indicator of disease severity and control. Nofal A; Al-Makhzangy I; Attwa E; Nassar A; Abdalmoati A J Eur Acad Dermatol Venereol; 2009 Jul; 23(7):803-6. PubMed ID: 19309427 [TBL] [Abstract][Full Text] [Related]
30. Evaluation of cytokine serum levels in patients with plaque-type psoriasis. Roussaki-Schulze AV; Kouskoukis C; Petinaki E; Klimi E; Zafiriou E; Galanos A; Rallis E Int J Clin Pharmacol Res; 2005; 25(4):169-73. PubMed ID: 16402633 [TBL] [Abstract][Full Text] [Related]
31. Ultrastructural findings and tumor necrosis factor-alpha and intercellular adhesion molecule-1 expression in psoriasis patients before and after oral cyclosporin A therapy. Eşrefoğlu M; Gül M; Seyhan M Ultrastruct Pathol; 2006; 30(1):95-102. PubMed ID: 16517475 [TBL] [Abstract][Full Text] [Related]
32. Soluble E-selectin in sera of patients with atopic dermatitis and psoriasis--correlation with disease activity. Czech W; Schöpf E; Kapp A Br J Dermatol; 1996 Jan; 134(1):17-21. PubMed ID: 8745880 [TBL] [Abstract][Full Text] [Related]
33. Bullous pemphigoid in a patient with psoriasis during the course of PUVA therapy: study by ELISA test. Barnadas MA; Gilaberte M; Pujol R; Agustí M; Gelpí C; Alomar A Int J Dermatol; 2006 Sep; 45(9):1089-92. PubMed ID: 16961518 [TBL] [Abstract][Full Text] [Related]
34. CD56brightCD16(-) NK cells accumulate in psoriatic skin in response to CXCL10 and CCL5 and exacerbate skin inflammation. Ottaviani C; Nasorri F; Bedini C; de Pità O; Girolomoni G; Cavani A Eur J Immunol; 2006 Jan; 36(1):118-28. PubMed ID: 16323244 [TBL] [Abstract][Full Text] [Related]
35. Deactivation of endothelium and reduction in angiogenesis in psoriatic skin and synovium by low dose infliximab therapy in combination with stable methotrexate therapy: a prospective single-centre study. Goedkoop AY; Kraan MC; Picavet DI; de Rie MA; Teunissen MB; Bos JD; Tak PP Arthritis Res Ther; 2004; 6(4):R326-34. PubMed ID: 15225368 [TBL] [Abstract][Full Text] [Related]
36. Downregulation of the inhibitor of apoptosis protein survivin in keratinocytes and endothelial cells in psoriasis skin following infliximab therapy. Markham T; Mathews C; Rogers S; Mullan R; Bresnihan B; Fitzgerald O; Veale DJ; Fearon U Br J Dermatol; 2006 Dec; 155(6):1191-6. PubMed ID: 17107388 [TBL] [Abstract][Full Text] [Related]
37. [Cutaneous lipids and psoriasis]. Vignale RA; Lasalvia E Med Cutan Ibero Lat Am; 1983; 11(1):7-10. PubMed ID: 6348444 [TBL] [Abstract][Full Text] [Related]
38. The immune detection and quantitation of antigenic cell-free Fc receptor by solid phase RIA employing monoclonal anti FcR antibody. Ran M; Dux Z; Anavi P; Witz IP Dev Biol Stand; 1984; 57():367-70. PubMed ID: 6526145 [TBL] [Abstract][Full Text] [Related]
39. Activation of lymphocytes alters Fc receptor-beta 2-microglobulin interrelationship on the lymphocyte surface. Sármay G; Gergely J Cell Immunol; 1983 May; 78(1):73-82. PubMed ID: 6189625 [TBL] [Abstract][Full Text] [Related]
40. Advanced protein glycation in psoriasis. Damasiewicz-Bodzek A; Wielkoszyński T J Eur Acad Dermatol Venereol; 2012 Feb; 26(2):172-9. PubMed ID: 21395695 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]